CL2022002364A1 - Vacuna contra el virus sars-cov-2 con adyuvante cpg - Google Patents

Vacuna contra el virus sars-cov-2 con adyuvante cpg

Info

Publication number
CL2022002364A1
CL2022002364A1 CL2022002364A CL2022002364A CL2022002364A1 CL 2022002364 A1 CL2022002364 A1 CL 2022002364A1 CL 2022002364 A CL2022002364 A CL 2022002364A CL 2022002364 A CL2022002364 A CL 2022002364A CL 2022002364 A1 CL2022002364 A1 CL 2022002364A1
Authority
CL
Chile
Prior art keywords
cov
virus
vaccine against
against sars
cpg adjuvant
Prior art date
Application number
CL2022002364A
Other languages
English (en)
Inventor
Meinke Andreas
Möhlen Michael
Reinisch Christoph
Schlegl Robert
Taucher Christian
d campbell John
Novack David
S Janssen Robert
Heindl-Wruss Jürgen
Original Assignee
Valneva Austria Gmbh
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Valneva Austria Gmbh, Dynavax Tech Corp filed Critical Valneva Austria Gmbh
Publication of CL2022002364A1 publication Critical patent/CL2022002364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Aquí se describen vacunas contra el SARS-CoV-2 con adyuvante CpG y composiciones y métodos para producir y administrar dichas vacunas a sujetos que las necesitan.
CL2022002364A 2020-03-01 2022-08-30 Vacuna contra el virus sars-cov-2 con adyuvante cpg CL2022002364A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062983737P 2020-03-01 2020-03-01
EP20168324 2020-04-06
EP20202124 2020-10-15
EP20211936 2020-12-04
EP21154645 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160933 2021-03-05

Publications (1)

Publication Number Publication Date
CL2022002364A1 true CL2022002364A1 (es) 2023-02-03

Family

ID=75267452

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002364A CL2022002364A1 (es) 2020-03-01 2022-08-30 Vacuna contra el virus sars-cov-2 con adyuvante cpg

Country Status (9)

Country Link
US (1) US11684669B2 (es)
JP (1) JP2023515908A (es)
AU (1) AU2021229710A1 (es)
CL (1) CL2022002364A1 (es)
CO (1) CO2022012545A2 (es)
EC (1) ECSP22072586A (es)
GB (1) GB2592769B (es)
IL (1) IL296071A (es)
WO (1) WO2021176434A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967326A1 (en) * 2020-09-10 2022-03-16 Immunethep, SA Immunogenic compositions
EP4288093A1 (en) * 2021-02-05 2023-12-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Adjuvanted mucosal subunit vaccines for preventing sars-cov-2 transmission and infection
CN113633764B (zh) * 2021-09-02 2024-05-14 中国食品药品检定研究院 一种含佐剂的新冠dna疫苗
CN113755421B (zh) * 2021-09-28 2024-04-12 梦芊细胞因子有限公司 一种用于covid-19的口服性疫苗及抗体加强剂
CN114276422B (zh) * 2021-11-09 2023-07-07 中国人民解放军总医院 新型冠状病毒s蛋白多肽抗原及其应用
IT202100031055A1 (it) * 2021-12-10 2022-03-10 Carlo Brogna Metodica di detenzione e rilevamento della proteina “spike” prodotta dai vaccini di ultima generazione, a vettore mrna, per immunizzare gli esseri umani e animali nella prevenzione e nel trattamento della malattia da coronavirus sars-cov-2
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2023250111A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections
US11654121B1 (en) 2022-06-22 2023-05-23 Flagship Pioneering Innovations Vi, Llc Combination therapies for the treatment of viral infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2301000C (en) 1997-08-28 2003-07-08 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
WO2000020039A1 (en) * 1998-10-05 2000-04-13 The Regents Of The University Of California Methods and adjuvants for stimulating mucosal immunity
CA2370708A1 (en) * 1999-04-20 2000-10-26 Smithkline Beecham Biologicals S.A. Vaccine comprising rsv antigen and cpg oligonucleotide
CA2376992A1 (en) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Use of cpg as an adjuvant for hiv vaccine
AP2002002592A0 (en) * 2000-01-31 2002-09-30 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
US20090017069A1 (en) * 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
WO2004092360A2 (en) * 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
EP1620547B1 (en) 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2008505050A (ja) 2003-12-10 2008-02-21 エイジェンシー フォア サイエンス テクノロジー アンド リサーチ Ｓａｒｓコロナウイルスｓタンパク質およびその使用
EP1737879B1 (en) 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
CN1827936A (zh) * 2005-03-04 2006-09-06 张准胜 一种既有建筑物隔震改造的方法与装置
WO2007122392A1 (en) * 2006-04-20 2007-11-01 King's College London Composition comprising a cytotoxic t-cell - inducing adjuvant
CN102851295B (zh) 2006-08-28 2015-01-07 长春华普生物技术有限公司 Toll 样受体调节性寡核苷酸及其用途
NZ620441A (en) * 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
CA2776195A1 (en) * 2009-09-30 2011-04-07 Toray Industries, Inc. Hepatitis c virus vaccine composition
CN102068692A (zh) * 2010-12-30 2011-05-25 北京民海生物科技有限公司 一种流感病毒裂解疫苗及其制备方法
DK3785730T3 (da) 2011-12-06 2024-05-06 Valneva Austria Gmbh Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
BR112015021970A2 (pt) * 2013-03-14 2017-07-18 Massachusetts Inst Technology composições à base de nanopartículas
US20210260181A1 (en) * 2014-09-16 2021-08-26 Altimmune, Inc Coronavirus immunogenic compositions and uses thereof
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
WO2017143024A2 (en) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018147265A1 (ja) * 2017-02-07 2018-08-16 京都府公立大学法人 病原性グラム陰性菌に対するワクチン
SG11201909584QA (en) * 2017-04-25 2019-11-28 Adjuvance Technologies Inc Triterpene saponin analogues
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
WO2021048221A1 (en) 2019-09-09 2021-03-18 Valneva Austria Gmbh Inactivation process for viruses
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021178318A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
EP4114463A4 (en) 2020-03-01 2023-09-06 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
MX2022010642A (es) 2020-03-01 2022-11-08 Dynavax Tech Corp Vacunas contra coronavirus que comprenden un agonista de tlr9.
US11213482B1 (en) * 2020-03-05 2022-01-04 University of Pittsburgh—Of the Commonwealth System of Higher Educat SARS-CoV-2 subunit vaccine and microneedle array delivery system
EP4114456A1 (en) 2020-03-06 2023-01-11 The Colorado State University Research Foundation Production of vaccines comprising inactivated sars-cov-2 viral particles
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
CN116234815A (zh) 2020-06-18 2023-06-06 高端疫苗生物制剂股份有限公司 抗新型冠状病毒之免疫组合物

Also Published As

Publication number Publication date
WO2021176434A1 (en) 2021-09-10
IL296071A (en) 2022-11-01
GB2592769B (en) 2022-05-04
GB202104898D0 (en) 2021-05-19
ECSP22072586A (es) 2022-10-31
CO2022012545A2 (es) 2022-12-09
US20230038284A1 (en) 2023-02-09
US11684669B2 (en) 2023-06-27
GB2592769A (en) 2021-09-08
JP2023515908A (ja) 2023-04-14
AU2021229710A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
UY39159A (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
MX2018007627A (es) Vacuna contra el virus del zika.
BR112022016054A2 (pt) Composições imunogênicas para coronavírus e usos das mesmas
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
PE20151588A1 (es) Vacuna contra el virus del dengue
CR10559A (es) Vacuna de influenza
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
CO2017007057A2 (es) Vacuna contra la fiebre aftosa
BR112015021523A2 (pt) composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa
AR088907A1 (es) Vacuna
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
BR112018008697A2 (pt) método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação.
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
CO2022013715A2 (es) Vacuna inactivada contra el virus sars-cov-2
CL2015003445A1 (es) Uso del virus de la necrosis nerviosa del jurel (sjnnv) para la protección de peces contra infección por el virus de la necrosis nerviosa del mero de manchas rojas (rgnnv); vacuna que comprende sjnnv; y método para proteger peces contra infección por rgnnv.